10-Q: BioNexus Gene Lab Q3 2025: Strategic Shifts Amid Losses

BioNexus Gene Lab Corp. reports a wider net loss for the nine months ended September 30, 2025, while pursuing strategic shifts into biotech CDMO and digital asset treasury.

Summary

• Net loss for the three months ended September 30, 2025, narrowed to $(708,991) from $(1,345,370) in the prior year.
• Net loss for the nine months ended September 30, 2025, widened to $(1,948,490) from $(1,250,023) in the prior year.
• Total revenue decreased by 3.3% to $2,543,823 for Q3 2025 and by 0.7% to $6,941,151 for the nine months ended September 30, 2025, compared to the respective prior periods.
• Gross profit increased by 15.7% to $377,685 for Q3 2025 and by 11.11% to $1,089,200 for the nine months ended September 30, 2025.
• Operating expenses decreased by 44.2% for Q3 2025 and by 2.98% for the nine months ended September 30, 2025.
• Cash and cash equivalents were $1.36 million, and total liquidity exceeded $5 million as of September 30, 2025.
• The company completed a 1-for-10 reverse stock split effective April 7, 2025.
• Chemrex Corporation Sdn. Bhd. is transitioning from industrial chemical trading to a biotechnology-focused Contract Development and Manufacturing Organization (CDMO).
• An Ethereum-focused treasury strategy was approved in March 2025.
• A non-binding term sheet was entered into with Fidelion Diagnostics Pte Ltd for a cross-equity investment and exclusive commercialization rights for the VitaGuard MRD platform in Southeast Asia.
• A non-binding Strategic Partnership Term Sheet was signed with BirchBioMed Inc. for a strategic equity investment and collaboration.
• A Form S-3 registration statement was filed on November 7, 2025, to register up to $100 million of securities, including an at-the-market (ATM) program for up to $20 million.
• A significant deficiency in internal controls was identified at the Chemrex subsidiary, related to documentation, delegation of approval authority, and timeliness of internal reporting.

Sentiment

Score: 4

Explanation: While the company is pursuing significant strategic growth initiatives, including a pivot towards higher-margin biotech sectors and innovative digital asset treasury management, its financial performance for the nine months ended September 30, 2025, shows a widening net loss and declining revenue. The substantial increase in provision for expected credit losses and identified internal control deficiencies at a subsidiary also contribute to a cautious sentiment. The Q3 results show some improvement in net loss and gross profit, but the overall nine-month trend and operational risks temper optimism.

Positives

• Net loss for the three months ended September 30, 2025, significantly narrowed to $(708,991) from $(1,345,370) in the prior year, representing a 47.3% improvement.
• Gross profit increased by 15.7% for Q3 2025 and 11.11% for the nine months ended September 30, 2025, driven by higher margins in the Chemrex segment and cost reallocation in MRNA Scientific.
• Operating expenses decreased by 44.2% for Q3 2025 and 2.98% for the nine months ended September 30, 2025, primarily due to lower sales and marketing and general and administrative expenses.
• MRNA Scientific's revenue increased by 86% for Q3 2025 due to more client referrals from diagnostic centers.
• Strong liquidity position with cash and cash equivalents of $1.36 million and total liquidity exceeding $5 million as of September 30, 2025.
• Clean capital structure with minimal outstanding debt, no preferred stock, convertible debt, or high-yield instruments.
• Achieved full Nasdaq compliance in April 2025, reinforcing market stability and investor confidence.
• Strategic partnerships with Fidelion Diagnostics for the VitaGuard MRD platform and BirchBioMed for FS2 topical platform, expanding the biotech portfolio and geographic reach.
• Transition of Chemrex into a biotechnology-focused CDMO is expected to lead to higher-margin biotech manufacturing contracts by 2026.
• Adoption of an Ethereum-focused treasury strategy aims to enhance capital efficiency and diversify reserves.

Negatives

• Net loss for the nine months ended September 30, 2025, widened to $(1,948,490) from $(1,250,023) in the prior year, representing a 55.9% increase.
• Total revenue decreased by 3.3% for Q3 2025 and 0.7% for the nine months ended September 30, 2025, mainly due to lower sales volume in the industrial chemicals segment.
• Other income decreased significantly by 76.9% for Q3 2025 and 70.76% for the nine months ended September 30, 2025, primarily due to lower bank interest, dividends, and fair value gains on investments, as well as reduced reversal of expected credit losses.
• Provision for expected credit losses increased by 7,306% for Q3 2025 and 75.80% for the nine months ended September 30, 2025, reflecting increased credit risk exposure and updated assessments of customer payment behavior.
• Foreign currency translation gain decreased significantly for both the three-month and nine-month periods compared to the prior year.
• Operating cash flow was negative, with $(2,799,444) used in operating activities for the nine months ended September 30, 2025.
• A significant deficiency was identified in internal controls at the Chemrex subsidiary related to documentation, delegation of approval authority, and timeliness of internal reporting.

Risks

• Uncertainty in industry demand for diagnostics, specialty chemicals, contract development and manufacturing (CDMO), and digital asset treasury strategies.
• Future sales of large blocks of securities may adversely impact the share price.
• Depth of the trading market in securities.
• There is no assurance that definitive agreements will be successfully negotiated and executed with Fidelion Diagnostics, or that the contemplated transaction will close on the expected terms or timeframe, if at all.
• Operational, cultural, and regulatory challenges may arise in integrating Fidelion's operations, technology, and personnel, particularly due to different regulatory frameworks in Singapore.
• Delays or difficulties in integration, obtaining necessary licenses, or achieving anticipated market adoption for the VitaGuard platform could materially and adversely affect business prospects and the expected benefits of the transaction.
• The market price of Ethereum has been, and may continue to be, highly volatile, which could materially impact the fair value of digital asset holdings and financial position.
• Evolving custody, transfer, and regulatory frameworks for digital assets in the U.S., Malaysia, and Singapore may impose additional compliance burdens or impact liquidity.
• Cybersecurity risks, including hacking and theft, may result in the loss of Ethereum holdings, and such losses may not be recoverable.
• The transition of Chemrex into a CDMO model involves execution risk and could result in revenue shortfalls during the conversion period.
• Delays or failures in completing facility upgrades, acquiring specialized manufacturing equipment, hiring qualified technical personnel, and obtaining Good Manufacturing Practice (GMP) certification and other regulatory approvals for the CDMO transition.
• Demand for intended CDMO services may not materialize at projected levels, which could adversely affect return on invested capital.

Future Outlook

Management believes current cash and expected financing under the proposed $20 million ATM program are sufficient to sustain operations for at least the next 12 months. The MRNA Scientific segment is expected to benefit from the integration of Fidelion Diagnostics technology, expanding its testing portfolio and geographic reach. Chemrex's Industrial Chemicals segment is projected to decrease in relative contribution as its Contract Development and Manufacturing Organization (CDMO) operations scale, with a gradual reallocation of revenue mix toward higher-margin biotech manufacturing contracts by 2026. The Investment Holding segment will incorporate Ethereum treasury activities as a strategic asset to enhance capital efficiency and diversification. The company intends to pursue selective mergers, acquisitions, and joint ventures that align with its long-term strategy, capitalizing on its clean balance sheet and low compliance cost profile. Regulatory submissions for the VitaGuard MRD platform in Singapore and Malaysia are planned for 2026.

Management Comments

• "Management believes current cash and expected financing under our proposed $20 million ATM program with Maxim Group LLC under our recently filed (but not yet effective) S-3 registration statement are sufficient for at least 12 months."
• "Our capital structure free of preferred stock, convertible debt, or high-yield instruments positions us favorably to pursue growth initiatives on shareholder-friendly terms."
• "Our leadership team remains fully committed and confident in maintaining robust compliance with Nasdaq listing standards. We view compliance as fundamental to our growth strategy and market credibility."
• "We believe this multi-pronged approach, centered on financial resilience, operational efficiency, and innovation, will allow the Company to deliver long-term shareholder value and act swiftly in a rapidly evolving global market."

Industry Context

The company operates across diverse sectors, including genomic screening, industrial chemicals, and digital asset treasury management. The strategic pivot of its Chemrex subsidiary towards a biotechnology-focused Contract Development and Manufacturing Organization (CDMO) aligns with a broader industry trend of outsourcing specialized manufacturing in the life sciences sector. The partnerships in precision diagnostics (Fidelion Diagnostics) and regenerative treatments (BirchBioMed) indicate a focus on expanding into high-growth biotech and healthcare markets in Southeast Asia. The adoption of an Ethereum-focused treasury strategy positions the company as an early mover among Nasdaq-listed entities in leveraging digital assets for capital management, reflecting increasing corporate interest in blockchain and cryptocurrencies.

Management Changes

Corporate Governance

Legal Proceedings

• There are presently no pending legal proceedings to which the Company or any of its property is subject, or any material proceedings to which any director, officer or affiliate of the Company, any owner of record or beneficially of more than five percent of any class of voting securities is a party or has a material interest adverse to the Company, and no such proceedings are known to the Company to be threatened or contemplated against it.

Related Party Transactions

• Revenue from related parties totaled $25,649 for the three months ended September 30, 2025, and $57,632 for the nine months ended September 30, 2025.
• Purchases from related parties amounted to $(7,233) for the three months ended September 30, 2025, and $(9,404) for the nine months ended September 30, 2025.
• Rental expenses to a related party were $(1,065) for the three months ended September 30, 2025, and $(3,156) for the nine months ended September 30, 2025.
• Balances related to these transactions are interest-free, unsecured, and subject to normal credit terms.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises (ATM program) and volatility risk from the Ethereum treasury strategy, but also potential for long-term value creation from strategic shifts and partnerships.
• Employees at Chemrex may experience changes in roles or skill requirements due to the transition to a CDMO model, with new hires expected for CDMO operations.
• Customers of MRNA Scientific may benefit from an expanded diagnostic testing portfolio, while Chemrex's industrial chemical customers may see a wind-down of operations, and new CDMO customers will emerge.
• Suppliers will see changes in relationships as Chemrex shifts its business model, impacting industrial chemical suppliers and creating new opportunities for biotech manufacturing suppliers.
• Creditors benefit from the company's minimal outstanding debt and strong liquidity position, providing financial stability.

Next Steps

• Negotiate and execute definitive agreements for the Fidelion Diagnostics cross-equity investment and commercialization rights.
• Initiate regulatory submissions for the VitaGuard MRD platform in Singapore and Malaysia in 2026.
• Continue phased implementation of Chemrex's CDMO transition, including facility upgrades, equipment procurement, and quality management system enhancements aimed at achieving Good Manufacturing Practice (GMP) certification.
• Actively monitor regulatory developments in relevant jurisdictions (Wyoming, Malaysia) to ensure compliance and optimize the Ethereum treasury strategy.
• Pursue selective mergers, acquisitions, and joint ventures that align with the long-term strategy.
• Complete the remediation plan for internal control deficiencies at the Chemrex subsidiary during fiscal year 2025.
• Await SEC effectiveness of the Form S-3 registration statement and file the applicable prospectus supplement for the ATM program.
• Negotiate a definitive agreement with BirchBioMed Inc. for the strategic equity investment and collaboration.

Key Dates

Recommendation

The company is undergoing a significant strategic transformation, pivoting towards higher-growth biotechnology sectors and innovative treasury management. While the Q3 2025 net loss narrowed and gross profit improved, the nine-month net loss widened, and revenue declined. The identified internal control deficiencies at a subsidiary and the inherent risks associated with new ventures and digital assets warrant caution. The planned capital raise and strategic partnerships offer future growth potential, but their successful execution and impact on profitability remain to be seen. A 'Hold' recommendation reflects a wait-and-see approach to evaluate the effectiveness of these strategic shifts and the remediation of internal control issues.

Keywords

Genomic screening, Industrial chemicals, Biotechnology, CDMO, Ethereum treasury, Precision diagnostics, MRD platform, Nasdaq compliance, SEC filing, Financial results, Strategic partnerships, Internal controls, Malaysia, Singapore